Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Report 2026

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Overview

• Chronic Obstructive Pulmonary Disease (COPD) Treatment market size has reached to $21.73 billion in 2025 • Expected to grow to $29.13 billion in 2030 at a compound annual growth rate (CAGR) of 6.2% • Growth Driver: Rising Smoking Rates And The Impending Surge In The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market • Market Trend: Innovations In Combination Medication • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Chronic Obstructive Pulmonary Disease (COPD) Treatment Market?

Chronic obstructive pulmonary disease (COPD) treatment refers to medical care given to a patient that helps manage the symptoms, slow the progression, and improve the overall quality of life of individuals with COPD. COPD is a progressive respiratory disease characterized by airflow obstruction, chronic inflammation, and damage to the lung tissue. The main types of drugs used for chronic obstructive pulmonary disease (COPD) treatment are combination therapy, bronchodilators, corticosteroids, phosphodiesterase type 4 inhibitors, mucokinetics, and other drug classes. A combination therapy refers to a therapeutic intervention in which more than one therapy is administered to the patient. Combination therapy includes treatment plans that call for giving patients a variety of tablets, each carrying a specific medication. It used to treat such diseases as chronic bronchitis and emphysema and majorly used by hospitals, clinics, and homecare.

What Is The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Growth Forecast?

The chronic obstructive pulmonary disease (copd) treatment market size is expected to see strong growth in the next few years. It will grow to $29.13 billion in 2030 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to growing adoption of combination therapies, expansion of homecare treatment models, increasing healthcare expenditure, rising copd diagnosis rates, innovation in inhalation drug delivery. Major trends in the forecast period include rising adoption of triple combination inhaler therapies, increasing shift toward home-based copd management, growing focus on early diagnosis and disease screening, expansion of generic and cost-effective copd drugs, higher use of non-pharmacological pulmonary rehabilitation.

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Segmentation

1) By Drug Class: Combination Therapy, Bronchodilators, Corticosteroids, Phosphodiesterase Type 4 Inhibitor, Mucokinetics, Other Drug Classes 2) By Type: Chronic Bronchitis, Emphysema 3) By End-User: Hospitals, Clinics, Homecare Settings Subsegments: 1) By Combination Therapy: Long-Acting Beta-Agonists (LABA) + Inhaled Corticosteroids (ICS), Long-Acting Muscarinic Antagonists (LAMA) + LABA, Triple Therapy (LAMA + LABA + ICS) 2) By Bronchodilators: Short-Acting Beta-Agonists (SABA), Long-Acting Beta-Agonists (LABA), Long-Acting Muscarinic Antagonists (LAMA) 3) By Corticosteroids: Inhaled Corticosteroids (ICS), Oral Corticosteroids, Injectable Corticosteroids 4) By Phosphodiesterase Type 4 Inhibitor: Roflumilast, Other PDE4 Inhibitors 5) By Mucokinetics: Expectorants, Mucolytics 6) By Other Drug Classes: Antibiotics, Antivirals, Antifungal Agents

What Is The Driver Of The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market?

The increasing prevalence of smoking is expected to propel the growth of the chronic obstructive pulmonary disease (COPD) treatment market going forward. Smoking refers to the inhalation of smoke, typically from burning substances such as tobacco, through the mouth. COPD treatment is preferred in individuals with smoking for improved breathing, enhanced quality of life, reduced exacerbations, improved exercise tolerance, increased longevity, and improved mental health. For instance, in July 2023, according to the World Health Organization, a Switzerland-based intergovernmental organization, more than 8 million people are killed by tobacco each year, including 1.3 million non-smokers who inhale second-hand smoke. Therefore, the increasing prevalence of smoking is driving the growth of the chronic obstructive pulmonary disease (COPD) treatment industry.

Key Players In The Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

Major companies operating in the chronic obstructive pulmonary disease (copd) treatment market are Almirall S.A., AstraZeneca plc, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis AG, Teva Pharmaceutical Industries Ltd., Chiesi Farmaceutici S.p.A, Sunovion Pharmaceuticals Inc., Dr. Reddy’s Laboratories Ltd., Sanofi S.A, Theravance Biopharma Inc., Verona Pharmaceuticals plc, Pfizer Inc., Mylan N.V., Orion Corporation, Cipla Limited, Glenmark Pharmaceuticals Limited, Biocon Limited, Lupin Limited, Mundipharma International Limited

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Trends and Insights

Major companies operating in the chronic obstructive pulmonary disease (COPD) treatment market are focusing on innovative products such as Vilfuro-G to drive revenues in their market. Vilfuro-G is the first fixed-dose triple combination medication (FDC) in the world designed to effectively treat chronic obstructive pulmonary disease (COPD. For instance, in November 2023, Lupin Limited, an India-based pharmaceutical company launched Vilfuro-G. The product comes in a fixed dose of one strength, and once daily dosage is advised. Vilfuro-G's introduction is anticipated to greatly improve COPD patients' lives and broaden Lupin's respiratory product line, demonstrating the company's dedication to providing patients and medical professionals with cutting-edge treatment choices. Vilfuro-G is the only fixed-dose combination (FDC) specially designed to combine glycopyrronium bromide, vilanterol, and fluticasone furoate for the long-term treatment and management of moderate to severe COPD.

What Are Latest Mergers And Acquisitions In The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market?

In March 2023, UC Davis Health, a US-based health system associated partnered with Propeller Health. This collaboration demonstrates a dedication to using digital health technologies to improve clinical outcomes and improve care for people with long-term illnesses such as asthma and COPD. The partnership uses Propeller's remote monitoring program which includes sensors, a mobile app, a web interface, and individualized support to provide individualized treatment for high-risk patients with these illnesses. Propeller Health is a US-based digital health company specializing in respiratory health.

Regional Insights

North America was the largest region in the chronic obstructive pulmonary disease (COPD) treatment market in 2025. Asia-Pacific is expected to be the global chronic obstructive pulmonary disease (COPD) treatment market report during the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Chronic Obstructive Pulmonary Disease (COPD) Treatment Market?

The chronic obstructive pulmonary disease (COPD) treatment market includes revenues earned by entities by providing services such as oxygen therapy, pulmonary rehabilitation, medication services, endobronchial valve therapy and non-invasive ventilation services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Report 2026?

The chronic obstructive pulmonary disease (copd) treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the chronic obstructive pulmonary disease (copd) treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.